Kidney Cancer, Version 2.2020 Featured Updates to the NCCN Guidelines

被引：176

作者：

Motzer, Robert J. ^{[1
]}

Jonasch, Eric ^{[2
]}

Michaelson, M. Dror ^{[3
]}

Nandagopal, Lakshminarayanan ^{[4
]}

Gore, John L. ^{[5
]}

George, Saby ^{[6
]}

Alva, Ajjai ^{[7
]}

Haas, Naomi ^{[8
]}

Harrison, Michael R. ^{[9
]}

Plimack, Elizabeth R. ^{[10
]}

Sosman, Jeffrey ^{[11
]}

Agarwal, Neeraj ^{[12
]}

Bhayani, Sam ^{[13
,14
]}

Choueiri, Toni K. ^{[15
]}

Costello, Brian A. ^{[16
]}

Derweesh, Ithaar H. ^{[17
]}

Gallagher, Thomas H. ^{[5
]}

Hancock, Steven L. ^{[18
]}

Kyriakopoulos, Christos ^{[19
]}

LaGrange, Chad ^{[20
]}

Lam, Elaine T. ^{[21
]}

Lau, Clayton ^{[22
]}

Lewis, Bryan ^{[23
]}

Manley, Brandon ^{[24
]}

McCreery, Brittany ^{[5
]}

McDonald, Andrew ^{[4
]}

Mortazavi, Amir ^{[25
,26
]}

Pierorazio, Phillip M. ^{[27
]}

Ponsky, Lee ^{[28
,29
]}

Redman, Bruce G. ^{[7
]}

Somer, Bradley ^{[30
]}

Wile, Geoffrey ^{[31
]}

Dwyer, Mary A. ^{[32
]}

Hammond, Lydia J. ^{[32
]}

Zuccarino-Catania, Griselda ^{[32
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Massachusetts Gen Hosp, Canc Center

[4] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[5] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[6] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[7] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[9] Duke Canc Inst, Durham, NC USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[13] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[14] Washington Univ, Sch Med, St Louis, MO 14263 USA

[15] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[16] Mayo Clin, Canc Ctr, Rochester, MN USA

[17] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[18] Stanford Canc Inst, Stanford, CA USA

[19] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[20] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[21] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[22] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[23] Kidney Canc Coalit, Philadelphia, PA USA

[24] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[25] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[26] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA

[27] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[28] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[29] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[30] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[31] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[32] Natl Comprehens Canc Network, Plymouth Meeting, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 11期

关键词：

RENAL-CELL CARCINOMA; RADIOSURGERY ONCOLOGY CONSORTIUM; MICROVASCULAR TUMOR INVASION; TNM STAGING SYSTEM; INTERFERON-ALPHA; DOSE INTERLEUKIN-2; PHASE-III; CLASSIFICATION; THERAPY; SIZE;

D O I：

10.6004/jnccn.2019.0054

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.

引用

页码：1279 / 1285

页数：7

共 34 条

[1] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].

Choueiri, Toni K. ;

Halabi, Susan ;

Sanford, Ben L. ;

Hahn, Olwen ;

Michaelson, M. Dror ;

Walsh, Meghara K. ;

Feldman, Darren R. ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

George, Daniel J. ;

Morris, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+

[2] Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor [J].

Dall'Oglio, Marcos F. ;

Antunes, Alberto A. ;

Sarkis, Alvaro S. ;

Crippa, Alexandre ;

Leite, Katia R. ;

Lucon, Antonio Marmo ;

Srougi, Miguel .

BJU INTERNATIONAL, 2007, 100 (03) :552-555

[3] Microvascular tumor invasion, tumor size and Fuhrman grade:: A pathological triad for prognostic evaluation of renal cell carcinoma [J].

Dall'Oglio, Marcos F. ;

Ribeiro Filho, Leopoldo Alves ;

Antunes, Alberto A. ;

Crippa, Alexandre ;

Nesrallah, Luciano ;

Goncalves, Pierre D. ;

Leite, Katia R. M. ;

Srougi, Miguel .

JOURNAL OF UROLOGY, 2007, 178 (02) :425-428

[4] Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma [J].

Ficarra, V ;

Schips, L ;

Guillé, F ;

Li, GR ;

De la Taille, A ;

Galetti, TP ;

Cindolo, L ;

Novara, G ;

Zigeuner, RE ;

Bratti, E ;

Tostain, J ;

Altieri, V ;

Abbou, CC ;

Artibani, W ;

Patard, JJ .

CANCER, 2005, 104 (05) :968-974

[5] Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort [J].

Frank, I ;

Blute, ML ;

Leibovich, BC ;

Cheville, JC ;

Lohse, CM ;

Zincke, H .

JOURNAL OF UROLOGY, 2005, 173 (06) :1889-1892

[6] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[7] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[8] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial [J].

Hutson, Thomas E. ;

Lesovoy, Vladimir ;

Al-Shukri, Salman ;

Stus, Viktor P. ;

Lipatov, Oleg N. ;

Bair, Angel H. ;

Rosbrook, Brad ;

Chen, Connie ;

Kim, Sinil ;

Vogelzang, Nicholas J. .

LANCET ONCOLOGY, 2013, 14 (13) :1287-1294

[9] Prognostic impact of tumor size on pT2 renal cell carcinoma: An international multicenter experience [J].

Klatte, Tobias ;

Patard, Jean-Jacques ;

Goel, Rakhee H. ;

Kleid, Mark D. ;

Guille, Francois ;

Lobel, Bernard ;

Abbou, Clement-Claude ;

De La Taille, Alexandre ;

Tostain, Jacques ;

Cindolo, Luca ;

Altieri, Vincenzo ;

Ficarra, Vincenzo ;

Artibani, Walter ;

Prayer-Galetti, Tommaso ;

Allhoff, Ernst Peter ;

Schips, Luigi ;

Zigeuner, Richard ;

Figlin, Robert A. ;

Kabbinavar, Fairooz F. ;

Pantuck, Allan J. ;

Belldegrun, Arie S. ;

Lam, John S. .

JOURNAL OF UROLOGY, 2007, 178 (01) :35-39

[10] Prognostic relevance of tumour size in T3a renal cell carcinoma: A multicentre experience [J].

Lam, John S. ;